Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus HYDRO SERP 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus HYDRO SERP 50.
AMTURNIDE vs HYDRO-SERP "50"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
10 mg to 20 mg orally once daily, with or without food.
Hydrochlorothiazide 50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination